Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 4/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20991255 | 0.95 | TSHR (0.34) | NPSR1GAATSHRTP53GRM5 | |
| SCHEMBL24974795 | 0.89 | MAP3K5 (0.32) | NPSR1GAATSHRTP53USP2 | |
| SCHEMBL17992585 | 0.85 | MAP3K5 (0.37) | NPSR1TSHRGRM5GRM1MEN1 | |
| SCHEMBL20807653 | 0.84 | TSHR (0.32) | NPSR1GAATSHRTP53KDM4E | |
| SCHEMBL16980276 | 0.84 | SMN1; SMN2 (0.32) | NPSR1GAATSHRTP53MEN1 | |
| SCHEMBL19170430 | 0.84 | GRM5 (0.34) | NPSR1TSHRGRM5GRM1MAP3K5 | |
| SCHEMBL26229453 | 0.84 | GRM5 (0.34) | GRM5GRM1MAP3K5POLBKDM4E | |
| SCHEMBL20999002 | 0.82 | GRM5 (0.33) | GRM5GRM1CYP3A4CYP2C9MAP3K5 | |
| SCHEMBL21189504 | 0.82 | NPSR1 (0.32) | NPSR1GAATSHRTP53USP2 | |
| SCHEMBL20215050 | 0.81 | NOTUM (0.33) | NPSR1TSHRKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210299286-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-09-30 | — | — | US | disclosed |
| US-10633374-B2 | Small molecule based antibody-recruiting compounds for cancer treatment | YALE UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| US-10316037-B1 | Compounds and methods for treating cancer | YALE UNIVERSITY (US) | 2019-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | NPSR1 518/4885GAA 553/4885TSHR 1233/4885 |
| US-10316037-B1 | Compounds and methods for treating cancer | ABCC1, PLK1, HDAC6 | NPSR1 3209/4885GAA 529/4885TSHR 4811/4885 |
| US-20210299286-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | FCER2, SQLE, TTL | NPSR1 189/4885GAA 1878/4885TSHR 1762/4885 |
| US-10633374-B2 | Small molecule based antibody-recruiting compounds for cancer treatment | PLAUR, C5AR1, C3AR1 | NPSR1 2793/4885GAA 2200/4885TSHR 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.